

## **Supplementary Material**

Article Title: A Proof-of-Concept Study of Subanesthetic Intravenous Ketamine Combined With

Prolonged Exposure Therapy Among Veterans With Posttraumatic Stress Disorder

**Author(s):** Paulo R. Shiroma, MD; Paul Thuras, PhD; Joseph Wels, MD; Christopher Erbes, PhD;

Shannon Kehle-Forbes, PhD; and Melissa Polusny, PhD

**DOI Number:** 10.4088/JCP.20I13406

## List of Supplementary Material for the article

1. Table 1 Demographic and Clinical Characteristics of Veterans with PTSD

Table 2 Number of Prolonged Exposure Sessions, and Severity of Post-traumatic Stress Disorder,

Major Depressive Disorder, and Clinical Global Impression at Baseline and Post-

Treatment

## **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

## Supplementary Table 1. Demographic and Clinical Characteristics of Veterans with PTSD

Patient	Age <sup>¥</sup>	Sex	Type of	Duration	MDD	Anxiety	PPH	Past	SA
N			Trauma	of PTSD <sup>¥</sup>		Disorder		SUD/AUD	
1	54	M	Combat	15	Yes	Yes	No	No	No
2	38	M	Sexual	23	No	No	No	No	Yes
3	42	F	Sexual	6	Yes	Yes	No	No	No
4	34	M	Combat	14	No	Yes	No	No	No
5	72	M	Combat	52	Yes	Yes	No	Yes	No
6	38	M	Combat	15	Yes	No	Yes	Yes	Yes
7	24	F	Sexual	15	No	Yes	No	No	No
8	36	M	Combat	5	Yes	No	No	No	No
9	47	F	Sexual	28	Yes	Yes	Yes	No	Yes
10	66	M	Physical	44	Yes	Yes	Yes	Yes	Yes

Abbreviations: M, Male; F, Female; \*in years. MDD: Major Depressive Disorder. PPH: Past Psychiatric Hospitalization. SUD, Substance Use Disorder; AUD, Alcohol Use Disorder: SA, Suicidal Attempt.

Supplementary Table 2. Number of Prolonged Exposure Sessions, and Severity of Post-traumatic Stress Disorder, Major Depressive Disorder, and Clinical Global Impression at Baseline and Post-Treatment

Patient	N of PE	CAPS-5	CAPS-5	PCL-5	PCL-5	MADRS	MADRS	CGI-S	CGI-S
N	sessions	Baseline	Post-	Baseline	Post-	Baseline	Post-	Baseline	Post-
			treatment <sup>¥</sup>		Treatment		treatment		Treatment
$1^{\#}$	7	30	2	49	9	30	4	5	3
2*	7	34	1	43	1	18	4	4	2
3**	7	48	22	61	7	18	6	5	2
4	10	33	16	45	21	18	15	4	3
5	10	56	25	71	21	34	15	5	3
6	6	45	N/A*	69	11	27	4	5	3
7	3	37	5	48	15	21	5	5	2
8 <sup>π</sup>	10	53	14	56	25	32	21	5	2
9 <sup>μ</sup>	10	50	15	63	17	26	11	5	2
10 π	10	42	18	58	28	26	22	5	3

Abbreviations: CAPS-5, Clinician-Administered PTSD Scale for DSM-5; PCL=5, PTSD Checklist for DSM-5; MADRS, Montgomery-Åsberg Depression Rating Scale. CGI-S: Clinical Global Impression Severity. \*CAPS-5 post-treatment was administered within one week after the last PE sessions. \*Missed CAPS-5 after PE session 4 and lost follow-up after PE session 6. \*Asymptomatic elevation of systolic and diastolic blood pressure of subjects #8 (173/119) and #10 (163/103) required administration of 5 mg of labetalol once at infusion 1 and 3, respectively. \*P Subject required 2 mg of ondansetron IV stat after experiencing nausea without vomiting during infusion 1 and 2. \*Subjects who ended PE therapy after session 7 as therapists considered that clinical goals were achieved.